Tracking and Cumulative Lifetime Exposure to IGF-I in 6,459 Healthy Individuals and in SGA Children Treated with GH

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Tracking and Cumulative Lifetime Exposure to IGF-I in 6,459 Healthy Individuals and in SGA Children Treated with GH. / Kjaer, Anna Sophie L; Jensen, Rikke Beck; Petersen, Jørgen H; Linneberg, Allan; Kårhus, Line Lund; Henriksen, Louise Scheutz; Johannsen, Trine Holm; Main, Katharina M; Hoffman, Andrew R; Juul, Anders.

I: The Journal of clinical endocrinology and metabolism, Bind 108, Nr. 3, 2023, s. 642–652.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Kjaer, ASL, Jensen, RB, Petersen, JH, Linneberg, A, Kårhus, LL, Henriksen, LS, Johannsen, TH, Main, KM, Hoffman, AR & Juul, A 2023, 'Tracking and Cumulative Lifetime Exposure to IGF-I in 6,459 Healthy Individuals and in SGA Children Treated with GH', The Journal of clinical endocrinology and metabolism, bind 108, nr. 3, s. 642–652. https://doi.org/10.1210/clinem/dgac605

APA

Kjaer, A. S. L., Jensen, R. B., Petersen, J. H., Linneberg, A., Kårhus, L. L., Henriksen, L. S., Johannsen, T. H., Main, K. M., Hoffman, A. R., & Juul, A. (2023). Tracking and Cumulative Lifetime Exposure to IGF-I in 6,459 Healthy Individuals and in SGA Children Treated with GH. The Journal of clinical endocrinology and metabolism, 108(3), 642–652. https://doi.org/10.1210/clinem/dgac605

Vancouver

Kjaer ASL, Jensen RB, Petersen JH, Linneberg A, Kårhus LL, Henriksen LS o.a. Tracking and Cumulative Lifetime Exposure to IGF-I in 6,459 Healthy Individuals and in SGA Children Treated with GH. The Journal of clinical endocrinology and metabolism. 2023;108(3):642–652. https://doi.org/10.1210/clinem/dgac605

Author

Kjaer, Anna Sophie L ; Jensen, Rikke Beck ; Petersen, Jørgen H ; Linneberg, Allan ; Kårhus, Line Lund ; Henriksen, Louise Scheutz ; Johannsen, Trine Holm ; Main, Katharina M ; Hoffman, Andrew R ; Juul, Anders. / Tracking and Cumulative Lifetime Exposure to IGF-I in 6,459 Healthy Individuals and in SGA Children Treated with GH. I: The Journal of clinical endocrinology and metabolism. 2023 ; Bind 108, Nr. 3. s. 642–652.

Bibtex

@article{9fc7596396a145c2bc381e33abf81fc5,

title = "Tracking and Cumulative Lifetime Exposure to IGF-I in 6,459 Healthy Individuals and in SGA Children Treated with GH",

abstract = "CONTEXT: Supraphysiological serum insulin-like growth-factor-I (IGF-I) concentrations have been a matter of concern in children treated with growth hormone (GH) because high IGF-I levels were associated with risk of later disease in former epidemiological studies.OBJECTIVE: To determine whether a single IGF-I measurement reliably reflects lifetime IGF-I exposure we evaluated intraindividual longitudinal tracking of IGF-I and IGF-binding-protein-3 (IGFBP-3) levels and we estimated cumulative lifetime exposure to IGF-I in healthy and GH-treated individuals.METHODS: We included 6,459 healthy participants (cross-sectional = 5,326; longitudinal = 1,133) aged 0----76 years (9,963 serum samples) and nine patients born small-for-gestational-age (SGA) with 238 serum samples during GH treatment.Intraindividual tracking of IGF-I and IGFBP-3 (SDS) was determined by intraclass correlation coefficients (ICC). Cumulative lifetime IGF-I exposure was estimated by area under the curve of the predicted SDS-trajectory from 0-76 years.RESULTS: For IGF-I (SDS), ICCs were 0.50 (95% CI: 0.47-0.53) for male and 0.53 (0.50-0.56) for female participants. Lifetime IGF-I exposure was significantly higher in female (mean 12,723 ± 3,691 SD) than in male participants (12,563 ± 3,393); p = 0.02. In SGA children, treatment with GH increased the lifetime exposure to IGF-I from 9,512 ± 1,889 to 11,271 ± 1,689, corresponding to an increase in lifetime IGF-I trajectory from -0.89 SD ± 0.57 to -0.35 SD ± 0.49.CONCLUSION: Since IGF-I and IGFBP-3 levels track throughout life, a single measurement reliably reflects lifetime exposure. GH therapy increased the lifetime exposure to IGF-I only slightly and it remained below the average lifetime exposure in the reference population.",

author = "Kjaer, {Anna Sophie L} and Jensen, {Rikke Beck} and Petersen, {J{\o}rgen H} and Allan Linneberg and K{\aa}rhus, {Line Lund} and Henriksen, {Louise Scheutz} and Johannsen, {Trine Holm} and Main, {Katharina M} and Hoffman, {Andrew R} and Anders Juul",

note = "{\textcopyright} The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.",

year = "2023",

doi = "10.1210/clinem/dgac605",

language = "English",

volume = "108",

pages = "642–652",

journal = "Journal of Clinical Endocrinology and Metabolism",

issn = "0021-972X",

publisher = "Oxford University Press",

number = "3",

}

RIS

TY - JOUR

T1 - Tracking and Cumulative Lifetime Exposure to IGF-I in 6,459 Healthy Individuals and in SGA Children Treated with GH

AU - Kjaer, Anna Sophie L

AU - Jensen, Rikke Beck

AU - Petersen, Jørgen H

AU - Linneberg, Allan

AU - Kårhus, Line Lund

AU - Henriksen, Louise Scheutz

AU - Johannsen, Trine Holm

AU - Main, Katharina M

AU - Hoffman, Andrew R

AU - Juul, Anders

PY - 2023

Y1 - 2023

N2 - CONTEXT: Supraphysiological serum insulin-like growth-factor-I (IGF-I) concentrations have been a matter of concern in children treated with growth hormone (GH) because high IGF-I levels were associated with risk of later disease in former epidemiological studies.OBJECTIVE: To determine whether a single IGF-I measurement reliably reflects lifetime IGF-I exposure we evaluated intraindividual longitudinal tracking of IGF-I and IGF-binding-protein-3 (IGFBP-3) levels and we estimated cumulative lifetime exposure to IGF-I in healthy and GH-treated individuals.METHODS: We included 6,459 healthy participants (cross-sectional = 5,326; longitudinal = 1,133) aged 0----76 years (9,963 serum samples) and nine patients born small-for-gestational-age (SGA) with 238 serum samples during GH treatment.Intraindividual tracking of IGF-I and IGFBP-3 (SDS) was determined by intraclass correlation coefficients (ICC). Cumulative lifetime IGF-I exposure was estimated by area under the curve of the predicted SDS-trajectory from 0-76 years.RESULTS: For IGF-I (SDS), ICCs were 0.50 (95% CI: 0.47-0.53) for male and 0.53 (0.50-0.56) for female participants. Lifetime IGF-I exposure was significantly higher in female (mean 12,723 ± 3,691 SD) than in male participants (12,563 ± 3,393); p = 0.02. In SGA children, treatment with GH increased the lifetime exposure to IGF-I from 9,512 ± 1,889 to 11,271 ± 1,689, corresponding to an increase in lifetime IGF-I trajectory from -0.89 SD ± 0.57 to -0.35 SD ± 0.49.CONCLUSION: Since IGF-I and IGFBP-3 levels track throughout life, a single measurement reliably reflects lifetime exposure. GH therapy increased the lifetime exposure to IGF-I only slightly and it remained below the average lifetime exposure in the reference population.

AB - CONTEXT: Supraphysiological serum insulin-like growth-factor-I (IGF-I) concentrations have been a matter of concern in children treated with growth hormone (GH) because high IGF-I levels were associated with risk of later disease in former epidemiological studies.OBJECTIVE: To determine whether a single IGF-I measurement reliably reflects lifetime IGF-I exposure we evaluated intraindividual longitudinal tracking of IGF-I and IGF-binding-protein-3 (IGFBP-3) levels and we estimated cumulative lifetime exposure to IGF-I in healthy and GH-treated individuals.METHODS: We included 6,459 healthy participants (cross-sectional = 5,326; longitudinal = 1,133) aged 0----76 years (9,963 serum samples) and nine patients born small-for-gestational-age (SGA) with 238 serum samples during GH treatment.Intraindividual tracking of IGF-I and IGFBP-3 (SDS) was determined by intraclass correlation coefficients (ICC). Cumulative lifetime IGF-I exposure was estimated by area under the curve of the predicted SDS-trajectory from 0-76 years.RESULTS: For IGF-I (SDS), ICCs were 0.50 (95% CI: 0.47-0.53) for male and 0.53 (0.50-0.56) for female participants. Lifetime IGF-I exposure was significantly higher in female (mean 12,723 ± 3,691 SD) than in male participants (12,563 ± 3,393); p = 0.02. In SGA children, treatment with GH increased the lifetime exposure to IGF-I from 9,512 ± 1,889 to 11,271 ± 1,689, corresponding to an increase in lifetime IGF-I trajectory from -0.89 SD ± 0.57 to -0.35 SD ± 0.49.CONCLUSION: Since IGF-I and IGFBP-3 levels track throughout life, a single measurement reliably reflects lifetime exposure. GH therapy increased the lifetime exposure to IGF-I only slightly and it remained below the average lifetime exposure in the reference population.

U2 - 10.1210/clinem/dgac605

DO - 10.1210/clinem/dgac605

M3 - Journal article

C2 - 36250350

VL - 108

SP - 642

EP - 652

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 3

ER -

ID: 331771912